Brief: Enlivex Says First Patient Dosed In Clinical Trial Of Allocetra In Covid-19 Patients
10/08/2020 13:56
Aug 10 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES DOSING OF FIRST PATIENT IN CLINICAL
TRIAL OF
ALLOCETRA IN COVID-19 PATIENTS WITH SEVERE ILLNESS RESPIRATORY
FAILURE
* ENLIVEX THERAPEUTICS LTD - PLANNED PHASE IIB TRIAL OF
ALLOCETRA
WILL BE CONTROLLED, RANDOMIZED STUDY THAT IS EXPECTED TO
COMMENCE IN Q4
Source text for Eikon: ID:nGNX3n435y
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment